Views: 0 Author: Site Editor Publish Time: 2026-11-03 Origin: Site
Autoimmune Top 5 | Disease Priorities for 2026
Originally published in Chinese on March 10, 2026. This commentary reflects information available as of March 10, 2026.
Over the past decade, immunology has been one of the most resilient areas of pharmaceutical innovation. Successive waves of TNF-α inhibitors, IL-17 and IL-23 therapies, and JAK inhibitors have transformed treatment for autoimmune and immune-mediated diseases, creating blockbuster products and a substantial global market.
The landscape is changing. From 2025 through early 2026, research and business development activity among multinational pharmaceutical companies highlighted three shifts:
· Research priorities are expanding beyond established indications such as rheumatoid arthritis (RA) and psoriasis toward refractory disease and areas of high unmet need.
· New mechanisms and targets are diversifying development strategies beyond established pathways.
· Modalities including chimeric antigen receptor T cells (CAR-T), bispecific antibodies and RNA-based therapies are extending into autoimmune disease, drawing on advances in oncology and other therapeutic areas.
Where do major-company pipelines and transactions point next? Lilly’s acquisition of Morphic Therapeutic in 2024 strengthened its oral integrin portfolio for inflammatory bowel disease. Sanofi’s subsequent acquisition of DR0201 expanded its immunology portfolio with a bispecific myeloid cell engager. Gilead’s collaboration with LEO Pharma advanced oral STAT6 inhibitors and degraders as a new approach to inflammatory disease.
HKeyBio’s take. In HKeyBio’s assessment, these developments mark a second wave of innovation in autoimmune disease R&D. Competition in established areas is intensifying, while new indications and technologies are opening further opportunities. The following five diseases stand out for their combination of market potential, unmet need and scope for innovation. Atopic dermatitis is included within the broader immune-mediated disease landscape.
Table 1. Five priority areas for development in 2026
Rank and disease | Global patients* | Market size* (USD) | Representative marketed therapies | Development opportunity |
1 IBD | 7–10 million | $22–25 billion | Vedolizumab (α4β7 integrin); risankizumab (IL-23); upadacitinib (JAK1) | A large established market, with growing opportunities for oral small molecules alongside biologics |
2 SLE | 4–5 million | $2–4 billion | Belimumab (BAFF); anifrolumab (IFNAR1) | Cell therapies and B-cell-directed approaches |
3 AD | 200–300 million | $18–22 billion | Dupilumab (IL-4Rα); upadacitinib (JAK1); tralokinumab (IL-13) | Validation of new targets and mechanism-led expansion into other indications |
4 Vitiligo | 30–40 million | $1–1.5 billion | Ruxolitinib cream (JAK1/2) | JAK-pathway validation and room for differentiated, durable treatments |
5 Alopecia areata | 50–80 million | $1.5–2.5 billion | Baricitinib (JAK1/2); ritlecitinib (JAK3/TEC) | An emerging indication with strong unmet demand and opportunities to build on dermatology development capabilities |
*Indicative estimates; patient populations and market sizes depend on definitions, geography and the measurement period.
Inflammatory bowel disease (IBD), encompassing ulcerative colitis (UC) and Crohn’s disease, remains a leading priority for developers seeking sustained scientific and commercial opportunity. Even as an established therapeutic area, it continues to attract substantial investment and research activity.
Why does IBD remain a core priority in 2026?
1. A large market with continued growth potential. The estimated global patient population of 7–10 million represents substantial treatment need. Wider adoption of biologics and oral small molecules is expanding access to advanced therapies, supporting continued growth in one of the largest markets for immune-mediated disease treatments.
2. An evolving competitive landscape with room for new mechanisms. Approved therapies already target IL-23, α4β7 integrin, sphingosine-1-phosphate (S1P) receptors and JAK signaling; TYK2 is also under investigation. Vedolizumab, risankizumab and upadacitinib illustrate the range of established mechanisms. Important needs remain:
· Many patients do not achieve adequate mucosal healing or sustained remission.
· Long-term antibody treatment can carry substantial cost and administration burdens, making adherence and convenience important considerations.
· Some patients have an inadequate initial response or lose response over time, creating a need for additional mechanisms and treatment strategies.
These needs create opportunities for differentiated therapies to gain clinical and commercial traction. HKeyBio’s four-dimensional IBD model portfolio is designed to represent multiple aspects of disease heterogeneity and support efficacy evaluation of agents targeting complementary pathways, including combination strategies, to inform clinical translation.
3. Major-company investment reinforces interest in oral small molecules. Lilly’s acquisition of Morphic Therapeutic, completed in August 2024, highlights sustained interest in orally administered integrin-directed small molecules for IBD. [1] Oral therapies are expanding the available approaches alongside antibodies, with convenience and potential economic advantages shaping development priorities. For smaller biotechnology companies, these priorities offer practical routes to differentiation.
If IBD represents sustained opportunity in an established field, systemic lupus erythematosus (SLE) represents renewed momentum in a particularly complex area of innovation. B cells, T cells, immune complexes and interferon signaling all contribute to its heterogeneous biology. Existing therapies have improved care, yet many patients—especially those with refractory disease—continue to experience inadequate control and a substantial treatment burden.
Advances in B-cell-directed treatment and cell therapy are bringing new approaches into focus. What are the three main drivers?
1. B-cell-directed therapies provide a foundation for innovation. Belimumab, which targets B-cell activating factor (BAFF), established an important clinical foundation for modifying B-cell biology in SLE. T-cell-engaging bispecific antibodies are building on that foundation as off-the-shelf approaches to deeper B-cell depletion. Roche’s CD20 × CD3 antibody mosunetuzumab has been evaluated in an early SLE study, with reported B-cell depletion and disease-activity signals providing a rationale for further investigation. [2] The magnitude and durability of clinical benefit require interpretation within the study design and follow-up. CD19 × CD3 and CD20 × CD3 programs are extending the field from B-cell modulation toward T-cell-mediated depletion.
2. Cell therapy offers a route toward sustained remission. Early clinical reports of CD19-directed CAR-T therapy have described deep B-cell depletion and sustained remission in selected patients with severe autoimmune disease, including SLE. These findings support the possibility of prolonged disease control and position SLE as an important potential indication for autoimmune CAR-T development. Novartis and Bristol Myers Squibb are among the major companies pursuing this field. Larger studies and longer follow-up will define patient selection, safety and durability, with the potential to meaningfully reshape treatment.
3. Substantial unmet need gives innovation clear value. SLE affects a large population and can involve multiple organs, with significant consequences for quality of life. Patients with refractory or organ-threatening disease particularly need more durable control. This creates a strong clinical and commercial rationale for differentiated targets, mechanisms and modalities that deliver meaningful improvements in outcomes.
Atopic dermatitis (AD) has been one of the most successful areas of immune-mediated disease development over the past decade. Dupilumab, an IL-4Rα-directed antibody developed by Sanofi and Regeneron, helped transform treatment and stimulated broad interest in new mechanisms. AD remains a major priority in inflammatory dermatology, with opportunities that can extend into related diseases.
Why continue to prioritize AD?
1. A platform for new targets and cross-indication development. AD provides an important clinical setting for evaluating mechanisms that may also be relevant to asthma and selected allergic diseases, including food allergy. Expansion into other indications—including psoriasis where a specific mechanism supports it—requires disease-specific evidence. OX40/OX40L, IL-31, TSLP and STAT6 illustrate the breadth of target interest. The IL-31 pathway has already progressed beyond clinical exploration: nemolizumab, which targets IL-31 receptor α, received US approval for AD in December 2024. [3] Gilead’s January 2025 agreement with LEO Pharma further illustrates interest in oral STAT6 inhibitors and degraders. [4]
Multitarget concepts, including OX40L/TNF-α and TSLP/IL-33 combinations, offer a rationale for addressing complementary pathways. HKeyBio’s upgraded HKEY-AIDMD3.0 model database supports investigation of potential combination effects and the selection of relevant models to guide differentiated development.
2. A large patient population and continuing demand for care. AD affects an estimated 200–300 million people globally, with moderate-to-severe disease estimated to account for approximately 10–15% of cases. A subset of these patients remains inadequately controlled with available therapies and needs additional options. Growing recognition and diagnosis of AD, together with increasing demand for effective care, support further market expansion.
3. Diverse modalities create multiple routes to innovation. The treatment landscape spans topical agents, biologics and oral small molecules. Bispecific antibodies and RNA-based approaches add further directions for exploration. Developers can therefore pursue opportunities through new target validation, improved treatment profiles or new modalities.
Vitiligo has attracted renewed attention following the clinical success of JAK inhibition. Topical ruxolitinib has expanded targeted treatment options and increased interest among major pharmaceutical companies and biotechnology developers. Earlier approaches, including topical corticosteroids and phototherapy, remain relevant, while incomplete responses and recurrence sustain the need for innovation.
Why does vitiligo deserve particular attention?
1. A large patient population with persistent treatment gaps. An estimated 30–40 million people worldwide are affected. Existing approaches offer benefits, but many patients still seek more effective and durable repigmentation, leaving substantial unmet need.
2. Defined clinical endpoints support efficient evaluation. The Vitiligo Area Scoring Index (VASI), including facial and total-body assessments, and repigmentation measures provide defined ways to evaluate treatment effects. These measures support focused study design and interpretable development decisions. The time needed for repigmentation, response durability and safety assessment still shapes trial duration and development requirements.
3. Room for differentiated therapies in a developing field. JAK inhibition is an important starting point for further innovation. Systemic programs were already in advanced clinical development before March 2026, including phase 3 studies of povorcitinib. [5] Opportunities remain for long-acting treatments, differentiated systemic immune modulation, and new targets or modalities that improve the extent and durability of repigmentation.
Alopecia areata (AA) is an autoimmune hair-loss disorder that can have a substantial effect on appearance, emotional well-being and quality of life. For many years, effective options for severe disease were limited. JAK-pathway therapies have expanded treatment possibilities and stimulated further development.
The success of baricitinib, a JAK1/2 inhibitor developed by Lilly and Incyte, validated JAK-pathway inhibition as a treatment approach in AA. Ritlecitinib, which targets JAK3 and TEC-family kinases, provides another approved option. What makes AA an attractive development priority?
1. Strong patient demand and substantial market potential. The estimated global patient population of 50–80 million reflects a substantial disease burden. Many patients place a high priority on effective treatment because hair loss affects daily life and psychosocial well-being. The historical lack of effective options for severe disease creates meaningful scope for therapies that address remaining needs.
2. Emerging mechanisms support continued innovation. Beyond JAK inhibition, research into IL-15 signaling, resident memory T cells and immune tolerance offers routes toward differentiated approaches and potentially more durable disease control. These mechanisms create opportunities for developers to address aspects of disease biology that current therapies may not fully resolve.
3. Dermatology capabilities can support development across indications. Shared expertise in cutaneous immunology, clinical assessment and model development can support efficient work across AA and AD programs. The diseases also have distinct biology: IL-4Rα- or TSLP-directed candidates require an AA-specific mechanistic rationale and clinical validation. Well-chosen opportunities to reuse platforms and research capabilities may improve development efficiency while maintaining indication-specific evidence standards.
In HKeyBio’s view, the second wave of autoimmune innovation brings new opportunities as competition in RA and psoriasis intensifies. IBD, SLE, AD, vitiligo and AA are five priority areas for 2026 because they combine sizeable treatment needs, meaningful market potential and room for new mechanisms and modalities.
As a specialist in autoimmune disease models, HKeyBio focuses on preclinical autoimmune research. Its core technical team brings more than 20 years of experience in autoimmune drug development. With approximately 300 autoimmune and allergic disease models, experience supporting more than 500 IND applications, and the upgraded HKEY-AIDMD3.0 model database, HKeyBio provides services spanning target validation, efficacy evaluation and investigational new drug (IND) application support to help partners advance their programs.
Author: Ding Ying | Scientific review: Chen Yu | Editor: Jing Yan
HKeyBio is a preclinical contract research organization specializing in in vivo efficacy services for autoimmune disease. Its core technical team has more than 20 years of experience in autoimmune drug development. The company is ISO 9001 certified, with molecular, cellular, pathology, small-animal and analytical testing facilities in Suzhou Industrial Park, and nonhuman primate research facilities in Guangxi and Suzhou.
HKeyBio has approximately 60 employees, and its project leaders hold master’s or doctoral degrees. The team has experience with more than 300 new-drug IND applications and supports partners in addressing complex questions throughout autoimmune drug development and regulatory submission.
· More than 50 nonhuman primate models of autoimmune disease.
· More than 300 animal models of autoimmune disease.
· Experience with more than 500 autoimmune disease IND applications.
[1] Lilly. Lilly completes acquisition of Morphic to improve outcomes and expand options for patients with inflammatory bowel disease. August 16, 2024. Source
[2] Roche. GA43191 mosunetuzumab study in systemic lupus erythematosus. Patient-facing study page and final results summary, August 2025. Source
[3] Galderma. US FDA approval of Nemluvio (nemolizumab) for moderate-to-severe atopic dermatitis. December 2024. Source
[4] Gilead and LEO Pharma. Strategic partnership to accelerate an oral STAT6 program. January 11, 2025. Source
[5] Incyte. Second-quarter 2025 financial results and pipeline update. July 29, 2025. Source
This article is provided for information only and does not constitute investment advice. Readers are responsible for their own decisions and any associated risks. References to companies and programs are intended for neutral industry discussion. No express or implied warranty is given as to the accuracy, reliability or completeness of the information. If you believe any content infringes your rights, please contact HKeyBio so that it can be reviewed and removed where appropriate.
